Drug Profile


Alternative Names: Aldoxorubicin hydrochloride; DOXO-EMCH; Doxorubicin-6-maleimidocaproyl hydrazone; INNO-206; Tumour-targeted doxorubicin conjugate - CytRx Corporation

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KTB Tumorforschungs
  • Developer CytRx Corporation
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Hydrazines; Maleimides; Pyrroles; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Soft tissue sarcoma; Pancreatic cancer; Glioblastoma; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Phase II Glioblastoma; Kaposi's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Chondrosarcoma; Osteosarcoma; Solid tumours

Most Recent Events

  • 28 Jul 2017 CytRx and NantCell agree to co-promote and co-develop Aldoxorubicin
  • 12 Jun 2017 CytRx completes a phase I trial in Solid tumours (Inoperable/Unresectable, Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (NCT02235688)
  • 06 Jun 2017 Efficacy and adverse event data from a phase III trial in Soft tissue sarcoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top